Kythera Biopharmaceuticals Announces Presentation of Positive Results from Second ATX-101 European Phase III Trial for Reduction of Submental Fat
6/11/2012 10:03:12 AM
LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) today announced the presentation of initial trial results from Study ATX-101-10-17, the second of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the aesthetic treatment of submental fat, which commonly presents as an undesirable double chin. Ashish Bhatia, MD, presented the results at the 8th Annual Vegas Cosmetic Surgery International Multispecialty Symposium in Las Vegas, Nevada, on June 10, 2012.
comments powered by